Actinium (NYSE: ATNM) details plan to regain NYSE American listing
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Actinium Pharmaceuticals, Inc. has submitted a compliance plan to NYSE American after being notified it is not meeting certain continued listing standards. The exchange requires stockholders’ equity of at least $4.0 million when a company has recorded losses in three of its four most recent fiscal years.
The plan outlines actions management intends to take to restore compliance and maintain the company’s NYSE American listing status. The filing does not detail the specific steps but confirms the plan was delivered on June 18, 2026, in response to the prior deficiency notice.
Positive
- None.
Negative
- NYSE American listing deficiency: Actinium Pharmaceuticals is not in compliance with a continued listing standard that requires stockholders’ equity of $4.0 million or more when losses have occurred in three of four recent fiscal years, creating a potential delisting risk if compliance is not restored.
Insights
Actinium faces NYSE listing deficiency but has submitted a remediation plan.
Actinium Pharmaceuticals confirms it is below NYSE American’s continued listing standard tied to stockholders’ equity of $4.0 million when a company has losses in three of four recent fiscal years. This raises the risk that its shares could eventually be delisted if compliance is not restored.
The company has sent NYSE American a compliance plan describing planned actions by management to regain compliance. Actual impact will depend on whether the exchange accepts this plan and on Actinium’s ability to execute it. Future company disclosures may clarify the exchange’s response and any deadlines imposed.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Equity requirement threshold: $4.0 million stockholders’ equity
Compliance plan submission date: June 18, 2026
Deficiency notice reference date: May 27, 2026
3 metrics
Equity requirement threshold
$4.0 million stockholders’ equity
Required under NYSE American Section 1003(a)(ii) for companies with losses
Compliance plan submission date
June 18, 2026
Date Actinium submitted its NYSE American compliance plan
Deficiency notice reference date
May 27, 2026
Previously reported date NYSE American notice was received
Key Terms
NYSE American, stockholders’ equity, continued listing standards, Section 1003(a)(ii), +1 more
5 terms
NYSE American financial
"In accordance with the NYSE American LLC (“NYSE American”) requirements, on June 18, 2026..."
NYSE American is a stock exchange where companies can list their shares to be bought and sold by investors. It functions like a marketplace, helping businesses raise money and providing investors with opportunities to buy ownership in these companies. Its role is important because it facilitates the trading of smaller or emerging companies, offering investors access to a broader range of investment options.
stockholders’ equity financial
"requires a listed company to maintain stockholders’ equity of $4.0 million or more..."
Stockholders’ equity is the portion of a company’s value that belongs to its owners after subtracting what the company owes from what it owns — like the equity in a house after paying the mortgage. For investors it shows the company’s net worth and can indicate financial strength, a cushion against losses, and the amount potentially available to support dividends or reinvestment; tracking changes helps assess whether the business is building or eroding owner value.
continued listing standards financial
"the Company was not in compliance with the continued listing standards set forth in Section 1003(a)(ii)..."
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.
Section 1003(a)(ii) regulatory
"standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide..."
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Actinium Pharmaceuticals (ATNM) announce regarding NYSE American on June 18, 2026?
Actinium Pharmaceuticals reported that it submitted a compliance plan to NYSE American on June 18, 2026. The plan outlines management’s intended actions to restore compliance with the exchange’s continued listing standards following a prior notice of deficiency.
Why is Actinium Pharmaceuticals currently out of compliance with NYSE American standards?
NYSE American notified Actinium that it is not complying with Section 1003(a)(ii) of the NYSE American Company Guide. That standard requires stockholders’ equity of at least $4.0 million when a company has reported losses in three of its four most recent fiscal years.
What is the $4.0 million stockholders’ equity requirement mentioned for Actinium Pharmaceuticals?
The $4.0 million figure is NYSE American’s minimum stockholders’ equity requirement under Section 1003(a)(ii) when a company has losses in three of its last four fiscal years. Falling below this threshold triggered the exchange’s notice to Actinium Pharmaceuticals.
How is Actinium Pharmaceuticals responding to the NYSE American deficiency notice?
Actinium has submitted a formal compliance plan to NYSE American, describing actions management intends to take to regain compliance. The filing confirms the plan’s submission but does not provide detailed steps or timelines for how compliance will be restored.
Does the NYSE American deficiency notice mean Actinium Pharmaceuticals will be delisted?
The notice alone does not mean immediate delisting. It indicates Actinium is currently below a continued listing standard and must work with NYSE American on its submitted compliance plan. Future exchange decisions will determine whether the listing can be maintained.